May 6 (Reuters) - Alere Inc
The test strip, PN 99008G2, measures how long it takes blood to clot in patients taking blood thinner warfarin and is used with Alere's INRatio2 PT/INR monitor.
The health diagnostics and services company said the adverse events were due to significantly different test results between the strip and the local laboratory plasma test.
"The root cause for this issue has not yet been determined; therefore Alere cannot determine the patient conditions or circumstances that may contribute to the discrepancy," the company said.
Alere has asked customers to immediately stop using the test strips.
The company said it has reported the complaints to the U.S. Food and Drug Administration.
Alere shares were unchanged at $35.51 in early trade on the Nasdaq on Tuesday.
(Reporting by Shailesh Kuber; Editing by Sriraj Kalluvila)
((Shailesh.Kuber@thomsonreuters.com)(within U.S. +1 646 223 8780, outside U.S. +91 80 6749 4738)(Reuters Messaging: shailesh.kuber.reuters.com@reuters.net))
Keywords: ALERE RECALL/BLOODCLOTSTRIPS




















